NCT00295763View on ClinicalTrials.gov

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

September 30, 2006

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

Thyrogen (thyrotropin alfa for injection)

"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."

Trial Locations (9)

21287

Johns Hopkins University, Baltimore

43210

Ohio State University, Columbus

56124

University of Pisa, Pisa

77030

MD Anderson Cancer Centre, Houston

80010

University of Colorado Health Sciences Centre, Aurora

92210

Centre Rene Huguenin, Saint-Cloud

94805

Institut Gustave Roussy, Villejuif

97080

University of Wurzburg, Würzburg

N6A 4G5

LHRI Research Services, London

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | Biotech Hunter | Biotech Hunter